Literature DB >> 31087715

Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden.

J Sun1, Y Zhan1, D Mariosa1, H Larsson1,2, C Almqvist1,3, C Ingre4, U Zagai1, Y Pawitan1, F Fang1.   

Abstract

BACKGROUND AND
PURPOSE: Previous animal studies have suggested a disrupted intestinal microbiome in amyotrophic lateral sclerosis (ALS). Due to the known effect of antibiotics on gut microflora, the potential role of antibiotics use on the risk of ALS deserves an investigation.
METHODS: A nested case-control study was conducted using several Swedish national registers. In all, 2484 ALS patients diagnosed between 1 July 2006 and 31 December 2013 were included as cases, and five controls per case individually matched to the case by sex, birth year and area of residence were randomly selected from the general Swedish population. Information on antibiotics prescriptions before ALS diagnosis was extracted from the Prescribed Drug Register for both cases and controls. A conditional logistic regression model was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs).
RESULTS: After accounting for potential diagnostic delay in ALS by excluding all prescriptions within 1 year before diagnosis, any antibiotics use was associated with a higher risk of ALS. The ORs (95% CIs) were 1.06 (0.94-1.19), 1.13 (1.00-1.28) and 1.18 (1.03-1.35) when comparing 1, 2-3 and ≥4 prescriptions to no prescription (P for trend = 0.0069). Similar results were noted for antibiotics used for respiratory infections and urinary tract as well as skin and soft tissue infections. Amongst different individual antibiotics, the risk of ALS was especially increased in relation to more than two prescriptions of beta-lactamase sensitive penicillin (OR 1.28; 95% CI 1.10-1.50).
CONCLUSIONS: Use of antibiotics, especially repeated, might be associated with a higher subsequent risk of ALS. © European Academy of Neurology 2019.

Entities:  

Keywords:  amyotrophic lateral sclerosis; antibiotics; nested case-control study; register-based

Year:  2019        PMID: 31087715     DOI: 10.1111/ene.13986

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  16 in total

1.  Amyotrophic lateral sclerosis and intestinal microbiota-toward establishing cause and effect.

Authors:  Marc Gotkine; Denise Kviatcovsky; Eran Elinav
Journal:  Gut Microbes       Date:  2020-06-05

2.  Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.

Authors:  Anna Gaimari; Michele Fusaroli; Emanuel Raschi; Elisa Baldin; Luca Vignatelli; Francesco Nonino; Fabrizio De Ponti; Jessica Mandrioli; Elisabetta Poluzzi
Journal:  Drug Saf       Date:  2022-05-24       Impact factor: 5.606

3.  Colonization of the Caenorhabditis elegans gut with human enteric bacterial pathogens leads to proteostasis disruption that is rescued by butyrate.

Authors:  Alyssa C Walker; Rohan Bhargava; Alfonso S Vaziriyan-Sani; Christine Pourciau; Emily T Donahue; Autumn S Dove; Michael J Gebhardt; Garrett L Ellward; Tony Romeo; Daniel M Czyż
Journal:  PLoS Pathog       Date:  2021-05-06       Impact factor: 6.823

Review 4.  Does modern research validate the ancient wisdom of gut flora and brain connection? A literature review of gut dysbiosis in neurological and neurosurgical disorders over the last decade.

Authors:  Pranati Sharma; Abhishek Agrawal
Journal:  Neurosurg Rev       Date:  2021-04-26       Impact factor: 2.800

Review 5.  The Role of the Microbiota-Gut-Brain Axis and Antibiotics in ALS and Neurodegenerative Diseases.

Authors:  Mark Obrenovich; Hayden Jaworski; Tara Tadimalla; Adil Mistry; Lorraine Sykes; George Perry; Robert A Bonomo
Journal:  Microorganisms       Date:  2020-05-23

Review 6.  Diet, Microbiota and Brain Health: Unraveling the Network Intersecting Metabolism and Neurodegeneration.

Authors:  Francesco Gentile; Pietro Emiliano Doneddu; Nilo Riva; Eduardo Nobile-Orazio; Angelo Quattrini
Journal:  Int J Mol Sci       Date:  2020-10-10       Impact factor: 5.923

Review 7.  The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS).

Authors:  Sarah L Boddy; Ilaria Giovannelli; Matilde Sassani; Johnathan Cooper-Knock; Michael P Snyder; Eran Segal; Eran Elinav; Lynne A Barker; Pamela J Shaw; Christopher J McDermott
Journal:  BMC Med       Date:  2021-01-20       Impact factor: 8.775

8.  Changes in the concentrations of trimethylamine N-oxide (TMAO) and its precursors in patients with amyotrophic lateral sclerosis.

Authors:  Lu Chen; Yong Chen; Mingming Zhao; Lemin Zheng; Dongsheng Fan
Journal:  Sci Rep       Date:  2020-09-16       Impact factor: 4.379

9.  Incidence, Prevalence and Geographical Clustering of Motor Neuron Disease in the Netherlands.

Authors:  Adriaan D de Jongh; Ruben P A van Eijk; Susan M Peters; Michael A van Es; Anja M C Horemans; Anneke J van der Kooi; Nicol C Voermans; Roel C H Vermeulen; Jan H Veldink; Leonard H van den Berg
Journal:  Neurology       Date:  2021-01-20       Impact factor: 9.910

10.  Application of a bioinformatic pipeline to RNA-seq data identifies novel virus-like sequence in human blood.

Authors:  Marko Melnick; Patrick Gonzales; Thomas J LaRocca; Yuping Song; Joanne Wuu; Michael Benatar; Björn Oskarsson; Leonard Petrucelli; Robin D Dowell; Christopher D Link; Mercedes Prudencio
Journal:  G3 (Bethesda)       Date:  2021-09-06       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.